

REMARKS

Claims 15 – 17 and 21 – 36 are pending in the present application. Claims 16, 17, 21-24, 26-32, 34 and 36 are withdrawn from consideration as being drawn to a non-elected invention. By the present amendment 21-24 are hereby canceled without prejudice or disclaimer, and claim 29 is hereby amended. The amendment, which corrects a typographical error, adds no new matter.

In view of the amendments and the following remarks, reconsideration of claims 15, 22, 25, 29, 33, and 35 is respectfully requested.

102 Rejections

Claims 15 and 25 are rejected under 35 USC 102 (b) as being anticipated by U.S. Patent No. 5,602,099 (hereinafter “the ‘099 patent”).

Claims 15 and 25 recite a peptide consisting of bromotyrosine and one or more amino acids. According to MPEP 2111.03, the transitional phrase “consisting of” excludes any element, step, or ingredient **not** specified in the claim. (See, MPEP 2111.3, third paragraph.) Thus the elected species peptide recited in amended claims 15 and 25 cannot contain anything other than bromotyrosine and one or more of the 20 amino acids known in the art, and represented in the Patent Office’s sequence listings by a specific three letter code.

The peptides shown in the sequence listing of the ‘099 patent all contain a chemical compound which is not known in the art to be a conventional amino acid, including SEQ ID NO. 14, which in addition to bromotyrosine and the amino acid known in the art as phenylalanine (designated Phe in the sequence listing) contains the chemical compound known as 1,2,3,4 hydroisoquinoline-3-carboxylic acid. As noted in the sequence listing, 1,2,3,4 hydroisoquinoline-3-carboxylic acid is a modified site and is designated by the three letter code Xaa, meaning that it is something other than one of the conventional 20 amino acids that are known in the art and that are represented by a specific three letter code in the Patent Office’s sequence listings. For the Examiner’s convenience, applicant has attached hereto page 60 of Molecular and Cellular Biology, which shows the 20 amino acids that are known in the art and

that are normally used to make proteins. Since SEQ ID NO. 14 of the '099 patent contains something in addition to bromotyrosine and one or more conventional amino acids, SEQ ID NO. 14 of the '099 patent does not anticipate claims 15 and 25 of the instant application.

103 Rejections

Claims 15, 25, 33, and 35 are rejected as being unpatentable over U.S. Patent No. 5,602,099 in view of U.S. Patent No. 6,319,686 (hereinafter "the '686 patent").

The '099 patent does not teach or suggest a peptide consisting of 3-bromotyrosine and one or more of the 20 conventional amino acids known in the art. All of the opioid receptor antagonists disclosed in the '099 patent contain a chemical compound which is not known in the art to be a conventional amino acid (See SEQ ID NOs. 1-35 of the '099 patent). Indeed, several of the peptides recited in the sequence listing of the '099 patent contain multiple chemical compounds that are not known in the art to be conventional amino acids. (See, SEQ ID NO. 1, which contains a modified tyrosine at position 1, and two chemical compounds designated xaa at position 2 and 3 of the pentapeptide, See also, SEQ ID NO. 2, which contains an unmodified tyrosine at position 1 and two chemical compounds designated xaa at position 2 and 3 of the tetrapeptide) Thus, the '099 patent would not motivate one of ordinary skill in the art to replace the unique chemical compounds disclosed in the peptides shown in the sequence listing of the '099 patent with a conventional amino acid.

The '686 patent does not provide the teachings or suggestions absent from the '099 patent. There is nothing in the '686 patent to suggest that the chemical compound located at position 2 or position 3 of the molecules recited in the Sequence Listing of the '099 patent should be replaced with a conventional amino acid, as is known in the art. Moreover, there is nothing in the '686 patent to suggest that the molecules whose structures are shown in column 2 and 3 of the '099 patent should be modified to form a peptide that consists of 3-bromotyrosine and one or more amino acids. Accordingly, the '686 patent, and the '099 patent do not render the reagents recited in claims 15, 25, 33, and 35 of the present application obvious.


In view of the amendments and remarks, Applicants submit that the elected species recited in claims 15, 25, 33, and 35 of the present application is allowable and

Appl. No. 09/931,287
Amdt. dated December 20, 2004
Reply to Office Action of October 21, 2004

request that claims 27, 29, 34, and 36 should be considered. Applicants also respectfully request prompt notification of allowance of claims 15, 25, 27, 29, and 33-36.

Respectfully submitted,

CALFEE, HALTER & GRISWOLD LLP

By 
Pamela A. Docherty, Reg. No. 40,591
(216) 622-8416



MOLECULAR AND CELLULAR BIOLOGY

STEPHEN L. WOLFE
University of California at Davis

Wadsworth Publishing Company
Belmont, California
A Division of Wadsworth, Inc.

To my son, Christopher

BIOLOGY PUBLISHER: Jack C. Carey
EDITORIAL ASSISTANTS: Kathryn Shea, Laura Jersild
DEVELOPMENTAL EDITOR: Mary Arbogast
PRODUCTION AND ART SUPERVISION:
Hal Lockwood, Christi Payne Fryday/Bookman
Productions
PRODUCTION COORDINATOR: Harold Humphrey
PRINT BUYER: Karen Hunt
PERMISSIONS EDITOR: Robert Kauser
COPY EDITOR: Elizabeth F. Gehman
PAGE MAKE-UP: Judith Levinson
TECHNICAL ILLUSTRATORS: Darwen and Vally
Hennings, John and Judy Waller, Illustrious, Inc.,
Academy ArtWorks, Inc., Precision Graphics
CHAPTER-OPENING ILLUSTRATORS: Chapters 1, 4, 5,
7, 9, 10, 12, 13, 14, 18, 20, 21, 24, 25, and 27 designed and
rendered by Darwen and Vally Hennings; Chapters 6, 8,
11, 19, 22, and 26 designed by Darwen Hennings and
rendered by Teresa Snyder; Chapters 2, 3, 15, 16, 17, and
23 designed and rendered by John and Judy Waller
COMPOSITOR: Syntax International
COLOR SEPARATOR: H&S Graphics, Inc.
PRINTER: R. R. Donnelley and Sons Company/Willard
COVER DESIGN: Stephen Rapley
COVER ILLUSTRATION: Tomo Narashima, based on a
design by Darwen and Vally Hennings

© 1993 by Wadsworth, Inc. All rights reserved. No part
of this book may be reproduced, stored in a retrieval
system, or transcribed, in any form or by any means,
without the prior written permission of the publisher,
Wadsworth Publishing Company, Belmont, California
94002.

12345678910 96 95 94 93

Library of Congress Cataloging-in-Publication Data

Wolfe, Stephen L.

Molecular and cellular biology / Stephen L. Wolfe.

p. cm.

Includes bibliographical references and index

ISBN 0-534-12408-9

1. Cytology. 2. Molecular biology. I. Title.

QH581.2.W646 1993



574.87-dc20

92-38636


BOOKS IN THE WADSWORTH BIOLOGY SERIES

Environmental Science, 3rd, Miller
Resource Conservation and Management, Miller
Biology: Concepts and Applications, Starr
Biology: The Unity and Diversity of Life, 6th, Starr and
Taggart
Biology of the Cell, 2nd, Wolfe
Cell Ultrastructure, Wolfe
Dimensions of Cancer, Kupchella
Evolution: Process and Product, 3rd, Dodson and Dodson
Introduction to Cell Biology, Wolfe
Oceanography: An Introduction, 4th, Ingmanson and
Wallace
Plant Physiology, 4th, Devlin and Witham
Exercises in Plant Physiology, Witham et al.
Plant Physiology, 4th, Salisbury and Ross
Plant Physiology Laboratory Manual, Ross
Plants: An Evolutionary Survey, 2nd, Scagel et al.
Psychobiology: The Neuron and Behavior, Hoyenga and
Hoyenga
Sex, Evolution, and Behavior, 2nd, Daly and Wilson


nonpolar amino acids



uncharged polar amino acids



negatively charged (acidic) polar amino acids



positively charged (basic) polar amino acids




Figure 2-18 The 20 amino acids used by ribosomes in protein synthesis. The side chains of each amino acid are boxed in color. One amino acid, proline, differs from the common structural plan (see text). Three-letter and one-letter abbreviations used for the amino acids appear below each structural diagram.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.